Drug Profile
Research programme: P80DOX-NP - Advectus
Alternative Names: Doxorubicin nanoparticle formulation; Doxorubicin nanoparticles - Advectus; P80 DOX-NPLatest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Advectus Life Sciences; University of North Carolina at Chapel Hill
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Sep 2006 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 01 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Jul 2002 Preclinical trials in Cancer in Canada (unspecified route)